武田与Protagonist宣布美国FDA受理Rusfertide新药申请并授予优先审评资格，该药有望成为真性红细胞增多症的首创疗法_老虎社区_美港股上老虎

武田与Protagonist宣布美国FDA受理Rusfertide新药申请并授予优先审评资格，该药有望成为真性红细胞增多症的首创疗法

美股速递03-02

武田制药与Protagonist Therapeutics Inc（纳斯达克代码：PTGX）共同宣布，美国食品药品监督管理局（FDA）已正式受理其联合研发药物Rusfertide的新药申请（NDA），并授予其优先审评资格。Rusfertide作为一种潜在的首创疗法，旨在用于治疗真性红细胞增多症患者。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1137079203?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-02 15:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137079203","market":"us","top_or_hot":-1,"title":"武田与Protagonist宣布美国FDA受理Rusfertide新药申请并授予优先审评资格，该药有望成为真性红细胞增多症的首创疗法","media":"美股速递","content":"<p>武田制药与Protagonist Therapeutics Inc（纳斯达克代码：PTGX）共同宣布，美国食品药品监督管理局（FDA）已正式受理其联合研发药物Rusfertide的新药申请（NDA），并授予其优先审评资格。Rusfertide作为一种潜在的首创疗法，旨在用于治疗真性红细胞增多症患者。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>武田与Protagonist宣布美国FDA受理Rusfertide新药申请并授予优先审评资格，该药有望成为真性红细胞增多症的首创疗法</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n武田与Protagonist宣布美国FDA受理Rusfertide新药申请并授予优先审评资格，该药有望成为真性红细胞增多症的首创疗法\n</h2>\n\n<h4 class=\"meta\">\n\n2026-03-02 15:04 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>武田制药与Protagonist Therapeutics Inc（纳斯达克代码：PTGX）共同宣布，美国食品药品监督管理局（FDA）已正式受理其联合研发药物Rusfertide的新药申请（NDA），并授予其优先审评资格。Rusfertide作为一种潜在的首创疗法，旨在用于治疗真性红细胞增多症患者。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTGX","symbol_name":"Protagonist Therapeutics Inc","start_time":0,"source_url":"","article_id":"1137079203","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137079203","pubTimestamp":1772435074,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"武田制药与Protagonist Therapeutics Inc（纳斯达克代码：PTGX）共同宣布，美国食品药品监督管理局（FDA）已正式受理其联合研发药物Rusfertide的新药申请（NDA），并授予其优先审评资格。Rusfertide作为一种潜在的首创疗法，旨在用于治疗真性红细胞增多症患者。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"PTGX":"Protagonist Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Takeda and Protagonist announced that the US FDA accepted the new drug application for Rusfertide and granted priority review status. The drug is expected to become the first treatment for polycythemia vera","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTGX":1},"content_text":"武田制药与Protagonist Therapeutics Inc（纳斯达克代码：PTGX）共同宣布，美国食品药品监督管理局（FDA）已正式受理其联合研发药物Rusfertide的新药申请（NDA），并授予其优先审评资格。Rusfertide作为一种潜在的首创疗法，旨在用于治疗真性红细胞增多症患者。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}